SYK
51
-4
CMG
67
-3
MDT
57
-2
PG
43
-3
CMS
60
2
ZBH
60
4
MHK
25
-5
TXT
49
-3
GOOG
81
-8
PEG
50
-5
PEP
33
-5
PPG
58
-2
CVX
28
-3
PYPL
56
-4
O
15
-2
PWR
67
-3
FOXA
67
4
PPL
37
-2
INTC
36
-3
LMT
27
2
SYK
51
-4
CMG
67
-3
MDT
57
-2
PG
43
-3
CMS
60
2
ZBH
60
4
MHK
25
-5
TXT
49
-3
GOOG
81
-8
PEG
50
-5
PEP
33
-5
PPG
58
-2
CVX
28
-3
PYPL
56
-4
O
15
-2
PWR
67
-3
FOXA
67
4
PPL
37
-2
INTC
36
-3
LMT
27
2
Financhill
Back

Perspective Therapeutics Quote, Financials, Valuation and Earnings

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
30

CATX
Perspective Therapeutics

Last Price:
3.19
Seasonality Move:
27.93%

7 Day Trial

ALL ACCESS PASS

$ 7

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Perspective Therapeutics Price Quote

$3.19
+0.12 (+3.91%)
(Updated: December 18, 2024 at 12:35 PM ET)

Perspective Therapeutics Key Stats

Sell
30
Perspective Therapeutics (CATX) is a Sell
Day range:
$3.07 - $3.47
52-week range:
$2.60 - $19.05
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
16.58
P/B ratio:
0.63%
Volume:
1.5M
Avg. volume:
2.2M
1-year change:
14.68%
Market cap:
$207.5M
Revenue:
$0
EPS:
$-1.46

How Much Does Perspective Therapeutics Make?

Data Unavailable

Is Perspective Therapeutics Growing As A Company?

Data Unavailable

Perspective Therapeutics Stock Price Performance

What Is Perspective Therapeutics 52-Week High & Low?

Perspective Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Perspective Therapeutics?

Is Perspective Therapeutics Cash Flow Positive?

  • What Is CATX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$696K
  • What Is Perspective Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $289.4M
  • What Is Perspective Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$80.4M

Perspective Therapeutics Return On Invested Capital

Data Unavailable

Perspective Therapeutics Earnings Date & Stock Price

Perspective Therapeutics Competitors

Perspective Therapeutics Dividend Yield

Perspective Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -3.06%
Revenue: 0% 55.1%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 16.15
Upside from Last Price: 426.06%

Major Shareholders

  • How many CATX shares are owned by institutional investors?
    79.5M CATX shares are owned by institutional investors
  • How many CATX shares are owned by insiders?
    4.3M CATX shares are owned by insiders